NCT01897571 - Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL | Biotech Hunter

Enrollment

400

Participants

Timeline

Start Date

June 13, 2013

Primary Completion Date

August 24, 2021

Study Completion Date

November 2, 2021

Conditions

B-cell Lymphomas (Phase 1)Advanced Solid Tumors (Phase 1)Diffuse Large B-cell Lymphoma (Phase 2)Follicular Lymphoma (Phase 2)Transformed Follicular LymphomaPrimary Mediastinal Large B-Cell Lymphoma

Interventions

DRUG

Tazemetostat

Patients who received 800 mg of tazemetostat, BID, administered in continuous 28-day cycles.

DRUG

Prednisolone

Patients who received 40 mg/m\^2 prednisolone once daily on Days 1-5 and 15-19 of Cycles 1-4.

DRUG

Tazemetostat

Patients who received 100 mg to 1600 mg of tazemetostat, BID, administered in continuous 28-day cycles.

Trial Locations (52)

10065

New York

20057

Washington D.C.

22031

Fairfax

34471

Ocala

35294

Birmingham

48109

Ann Arbor

77030

Houston

78217

San Antonio

80012

Aurora

91010

Duarte

93105

Santa Barbara

98122

Seattle

Unknown

Clayton

Geelong

Melbourne

Montreal

Toronto

Bordeaux

Caen

Créteil

Lille

Lyon

Marseille

Montpellier

Nantes

Paris

Pierre-Bénite

Rennes

Rouen

Villejuif

Göttingen

Münster

Bologna

Napoli

Krakow

Lublin

Poznan

Warsaw

Taipei

Chernivtsi

Dnipro

Ivano-Frankivsk

Kharkiv

Kyiv

Mykolayiv

Uzhhorod

Zaporizhzhya

Zhytomyr

Glasgow

London

Manchester

Southampton